(Another!) FDA trial design workshop: Complex innovative designs

Dear All:

Adding to the 19 Mar 2018 (Designs for Rare Diseases) and 16 Apr 2018 (Inclusion/Exclusion criteria) workshops already announced (see list below), FDA has now announced a 20 Mar 2018 workshop on complex innovative designs (CID) in clinical drug trials. From the Federal Register notice, we are told that the workshop seeks to (1) facilitate discussion and information sharing about the use of CID in drug development and regulatory decision making and (2) obtain input from stakeholders about a CID pilot program. Ideas to be discussed include complex adaptive designs, use of external/historical control subjects, Bayesian designs, master protocols, clinical trial simulations, and the proposed CID pilot program.

Why is this relevant to those of us working on new approaches to antimicrobial resistance (AMR)? Although AMR does not appear in the titles of any of these workshops, some of the ideas could be (or could become) very relevant for the AMR community.

In particular, the mathematics of rare events make it hard to develop narrow-spectrum agents outside of a few special situations. As non-traditional alternative therapies are often narrow-spectrum (e.g., most monoclonal antibody approaches), we simply must find ways forward lest we never develop such products. 

We’ve had several public discussions on this problem (see this note for further details) and we’re definitely not done with the conversation. As the ideas to be discussed in the upcoming workshops might help us with trial designs for narrow-spectrum products, I’m delighted to see them on the calendar! Also, the mention of a pilot program for complex innovative designs is new and of interest. 

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:


17 April 2023: FREE Masterclass from FDA / CARB-X wants you!

Dear All, Two quick items today. First, FDA have announced an Antimicrobial Drugs Advisory Committee on 17 April 2023 (9a-4.30p ET). The committee will “discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is for the treatment of infections due to Acinetobacter baumannii-calcoaceticus complex including multidrug-resistant and

WHO 2023 Pipeline Update: Share Your Preclinical Antibacterial Projects!

Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://amr.solutions/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Scroll to Top